Label: EUTHANASIA- pentobarbital sodium and phenytoin sodium injection, solution

  • NDC Code(s): 11695-6990-1
  • Packager: BUTLER ANIMAL HEALTH SUPPLY, LLC DBA COVETRUS NORTH AMERICA
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: CIII
  • Marketing Status: Abbreviated New Animal Drug Application

Drug Label Information

Updated February 11, 2022

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    FOR DOGS ONLY

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION:

    A nonsterile solution containing pentobarbital sodium and phenytoin sodium as the active ingredients. Rhodamine B, a bluish-red fluorescent dye, is included in the formulation to help distinguish it from parenteral drugs intended for therapeutic use. Although the solution is not sterile, benzyl alcohol, a bacteriostat, is included to retard the growth of microorganisms.

    Each mL contains: active ingredients: 390 mg pentobarbital sodium (barbituric acid derivative), 50 mg phenytoin sodium; inactive ingredients: 10% ethyl alcohol, 18% propylene glycol, 0.003688 mg rhodamine B, 2% benzyl alcohol (preservative), purified water qs. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

  • ACTIONS:

    Euthanasia solution CIII (Pentobarbital sodium and phenytoin sodium) contains two active ingredients which are chemically compatible but pharmacologically different. Each ingredient acts in such a manner so as to cause humane, painless, and rapid euthanasia. Euthanasia is due to cerebral death in conjunction with respiratory arrest and circulatory collapse. Cerebral death occurs prior to cessation of cardiac activity.

    When administered intravenously, pentobarbital sodium produces rapid anesthetic action. There is a smooth and rapid onset of unconsciousness. At the lethal dose, there is depression of vital medullary respiratory and vasomotor centers.

    When administered intravenously, phenytoin sodium produces toxic signs of cardiovascular collapse and/or central nervous system depression. Hypotension occurs when the drug is administered rapidly.

    Pharmacodynamic Activity: The sequence of events leading to humane, painless, and rapid euthanasia following intravenous injection of Euthanasia solution CIII (Pentobarbital sodium and phenytoin sodium) is similar to that following intravenous injection of pentobarbital sodium or other barbituric acid derivatives. Within seconds, unconsciousness is induced with simultaneous collapse of the dog. This stage rapidly progresses to deep anesthesia with concomitant reduction in the blood pressure. A few seconds later, breathing stops, due to depression of the medullary respiratory center; encephalographic activity becomes isoelectric, indicating cerebral death, and then cardiac activity ceases.

    Phenytoin sodium exerts its effect during the deep anesthesia stage caused by the pentobarbital sodium. This ingredient, due to its cardiotoxic properties, hastens the stoppage of electrical activity in the heart.

  • INDICATIONS:

    For use in dogs for humane, painless, and rapid euthanasia.

  • WARNING:

    For canine euthanasia only. Must not be used for therapeutic purposes. Do not use in animals intended for food.

  • BOXED WARNING (What is this?)

    ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife.

  • HUMAN WARNING:

    Caution should be exercised to avoid contact of the drug with open wounds or accidental self-inflicted injections. Keep out of reach of children.

    If eye contact, flush eyes with water and seek medical attention.

  • PRECAUTIONS:

    Euthanasia may sometimes be delayed in dogs with severe cardiac or circulatory deficiencies. This may be explained by the impaired movement of the drug to its site of action. An occasional dog may elicit reflex responses manifested by motor movement; however, an unconscious animal does not experience pain, because the cerebral cortex is not functioning.

    When restraint may cause the dog pain, injury, or anxiety, or danger to the person making the injection, prior use of tranquilizing or immobilizing drugs may be necessary.

  • DOSAGE AND ADMINISTRATION

    Dosage: Dogs, 1 mL for each 10 pounds of body weight.

    Administration: Intravenous injection is preferred. Intracardiac injection may be made when intravenous injection is impractical, as in a very small dog or in a comatose dog with impaired vascular functions. Good injection skill is necessary for intracardiac injection.

    The calculated dose should be given in a single bolus injection.

    For intravenous injection, a needle of sufficient gauge to ensure intravenous placement of the entire dose should be used. The use of a Luer-Lok® syringe is recommended to prevent accidental exposure due to needle/syringe separation.

  • ADVERSE REACTION:

    To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Covetrus North America at (855) 724-3461. For additional information about adverse drug experience reporting for animal drugs,contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

  • HOW SUPPLIED:

    Euthanasia solution CIII (Pentobarbital sodium and phenytoin sodium) is available in 100 mL multi-dose vials in package of one, NDC 11695-6990-1.

    Manufactured by a nonsterilizing process.

    Store at controlled room temperature 20° to 25°C (68° to 77°F).

    Use contents within 60 days of first puncture.

    Approved by FDA under ANADA # 200-614

    covetrus®

    Distributed by:
    Covetrus North America
    400 Metro Place North
    Dublin, OH 43017

    covetrus.com

    AH-072934-01
    HVPP00N          REV: 0421

    Luer-Lok is a registered trademark of Becton, Dickinson and Company.

  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel Text for Container Label:

    covetrus® logo

    NDC 11695-6990-1

    Euthanasia solution

    (Pentobarbital sodium and

    phenytoin sodium) CIII

    FOR DOGS ONLY

    Caution: Federal law restricts this drug to use

    by or on the order of a licensed veterinarian.

    Approved by FDA under ANADA # 200-614

    Reorder #072934

    Net contents: 100 mL

    Principal Display Panel Text for Container Label
  • PRINCIPAL DISPLAY PANEL

    Principal Display Panel Text for Carton Label:

    covetrus® logo

    NDC 11695-6990-1

    Euthanasia

    solution

    (Pentobarbital CIII

    sodium and

    phenytoin sodium)

    FOR DOGS ONLY

    Caution: Federal law restricts

    this drug to use by or on the

    order of a licensed veterinarian.

    Approved by FDA under

    ANADA # 200-614

    Reorder #072934

    Net contents: 100 mL

    Principal Display Panel Text for Carton Label
  • INGREDIENTS AND APPEARANCE
    EUTHANASIA 
    pentobarbital sodium and phenytoin sodium injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:11695-6990
    Route of AdministrationINTRACARDIAC, INTRAVENOUSDEA ScheduleCIII    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Pentobarbital Sodium (UNII: NJJ0475N0S) (Pentobarbital - UNII:I4744080IR) Pentobarbital Sodium390 mg  in 1 mL
    Phenytoin Sodium (UNII: 4182431BJH) (Phenytoin - UNII:6158TKW0C5) Phenytoin Sodium50 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Alcohol (UNII: 3K9958V90M)  
    Propylene Glycol (UNII: 6DC9Q167V3)  
    Rhodamine B (UNII: K7G5SCF8IL)  
    Sodium Hydroxide (UNII: 55X04QC32I)  
    Hydrochloric Acid (UNII: QTT17582CB)  
    Water (UNII: 059QF0KO0R)  
    Benzyl Alcohol (UNII: LKG8494WBH)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:11695-6990-11 in 1 CARTON
    1100 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20061405/03/2021
    Labeler - BUTLER ANIMAL HEALTH SUPPLY, LLC DBA COVETRUS NORTH AMERICA (603750329)
    Registrant - AKORN OPERATING COMPANY LLC (117693100)
    Establishment
    NameAddressID/FEIBusiness Operations
    Akorn117696908LABEL, MANUFACTURE, PACK